What's Going On With Nektar Therapeutics Stock On Thursday? Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.
Why Is Sanofi Stock Falling Thursday? William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi.
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.
Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount.
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.
Why Thermo Fischer Stock Is Rising Wednesday Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook.
